Corbus Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Corbus Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Corbus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director HOLMER ALAN F
Corbus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Jenkins John Kenneth
Corbus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director CATLIN AVERY W
Corbus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Salzmann Peter
Corbus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director HOLMER ALAN F
Corbus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Ben Yong
Corbus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Jacques Rachelle Suzanne
Corbus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Altmeyer Anne
Corbus Pharmaceuticals | 8-K: Current report
Corbus Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Corbus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Salzmann Peter
Corbus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director HOLMER ALAN F
Corbus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Jenkins John Kenneth
Corbus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Jacques Rachelle Suzanne
Corbus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Altmeyer Anne
Corbus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Ben Yong
Corbus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director CATLIN AVERY W
Corbus Pharmaceuticals | 8-K: Current report
No Data